View Item 

Show simple item record

Treatment‐associated toxicities reported by patients with early‐stage invasive breast cancer
dc.contributor.authorFriese, Christopher R.
dc.contributor.authorHarrison, Jordan M.
dc.contributor.authorJanz, Nancy K.
dc.contributor.authorJagsi, Reshma
dc.contributor.authorMorrow, Monica
dc.contributor.authorLi, Yun
dc.contributor.authorHamilton, Ann S.
dc.contributor.authorWard, Kevin C.
dc.contributor.authorKurian, Allison W.
dc.contributor.authorKatz, Steven J.
dc.contributor.authorHofer, Timothy P.
dc.date.accessioned2017-06-16T20:16:32Z
dc.date.available2018-08-07T15:51:23Zen
dc.date.issued2017-06-01
dc.identifier.citationFriese, Christopher R.; Harrison, Jordan M.; Janz, Nancy K.; Jagsi, Reshma; Morrow, Monica; Li, Yun; Hamilton, Ann S.; Ward, Kevin C.; Kurian, Allison W.; Katz, Steven J.; Hofer, Timothy P. (2017). "Treatment‐associated toxicities reported by patients with early‐stage invasive breast cancer." Cancer 123(11): 1925-1934.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/137593
dc.publisherJohn Wiley & Sons Inc
dc.subject.otherpatient report
dc.subject.othertreatment‐associated toxicities
dc.subject.othertreatment experience
dc.subject.otherbreast cancer
dc.titleTreatment‐associated toxicities reported by patients with early‐stage invasive breast cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137593/1/cncr30547_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137593/2/cncr30547.pdf
dc.identifier.doi10.1002/cncr.30547
dc.identifier.sourceCancer
dc.identifier.citedreferenceGilmore JW, Peacock NW, Gu A, et al. Antiemetic guideline consistency and incidence of chemotherapy‐induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract. 2014; 10: 68 – 74.
dc.identifier.citedreferenceVandyk AD, Harrison MB, Macartney G, Ross‐White A, Stacey D. Emergency department visits for symptoms experienced by oncology patients: a systematic review. Support Care Cancer. 2012; 20: 1589 – 1599.
dc.identifier.citedreferenceKlepin BH, Pitcher BN, Ballman KV, et al. Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). J Oncol Pract. 2014; 10: e285 – e292.
dc.identifier.citedreferenceMartinez KA, Friese CR, Kershaw T, Given CW, Fendrick M, Northouse L. Effect of a nurse‐led psychoeducational intervention on healthcare service utilization among adults with advanced cancer. Oncol Nurs Forum. 2015; 42: E310 – E318.
dc.identifier.citedreferencePaessens BJ, von Schilling C, Berger K, et al. Health resource consumption and costs attributable to chemotherapy‐induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Ann Oncol. 2011; 22: 2310 – 2319.
dc.identifier.citedreferenceLamont EB, Herndon JE 2nd, Weeks JC, et al; Cancer and Leukemia Group B. Measuring clinically significant chemotherapy‐related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008; 46: 303 – 308.
dc.identifier.citedreferenceBarcenas CH, Niu J, Zhang N, et al. Risk of hospitalization according to chemotherapy regimen in early‐stage breast cancer. J Clin Oncol. 2014; 32: 2010 – 2017.
dc.identifier.citedreferenceHassett MJ, Rao SR, Brozovic S, et al. Chemotherapy‐related hospitalization among community cancer center patients. Oncologist. 2011; 16: 378 – 387.
dc.identifier.citedreferenceDueck AC, Mendoza TR, Mitchell S, et al; National Cancer Institute PRO‐CTCAE Study Group. Validity and reliability of the US National Cancer Institute’s Patient‐Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE). JAMA Oncol. 2015; 1: 1051 – 1059.
dc.identifier.citedreferenceAtkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012; 21: 1159 – 1164.
dc.identifier.citedreferenceDillman DA, Smyth JD, Christian LM. Internet, Phone, Mail, and Mixed‐Mode Surveys: The Tailored Design Method. 4th ed. Hoboken, NJ: John Wiley & Sons Inc; 2014.
dc.identifier.citedreferenceHamilton AS, Hofer TP, Hawley ST, et al. Latinas and breast cancer outcomes: population‐based sampling, ethnic identity, and acculturation assessment. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2022 – 2029.
dc.identifier.citedreferenceBasch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient‐reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE). J Natl Cancer Inst. 2014; 106 ( 9 ).
dc.identifier.citedreferenceHarrison JM, Stella PJ, LaVasseur B, et al. Toxicity‐related factors associated with use of services among community oncology patients. J Oncol Pract. 2016; 12: e818 – e827.
dc.identifier.citedreferenceSchalet BD, Hays RD, Jensen SE, Beaumont JL, Fries JF, Cella D. Validity of PROMIS physical function measured in diverse clinical samples. J Clin Epidemiol. 2016; 73: 112 – 118.
dc.identifier.citedreferencePatient‐Reported Outcomes Measurement Information System. PROMIS Physical Function Scoring Manual. https://www.assessmentcenter.net/documents/PROMISPhysicalFunctionScoringManual.pdf. Accessed May 31, 2016.
dc.identifier.citedreferenceGroves RM, Fowler FJ Jr, Couper MP, Lepkowski JM, Singer E, Tourangeau R. Survey Methodology. Hoboken, NJ: John Wiley & Sons Inc; 2011.
dc.identifier.citedreferenceRaghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. http://www.statcan.gc.ca/pub/12-001-x/index-eng.htm. Surv Methodol. 2001; 27: 85 – 95.
dc.identifier.citedreferenceRubin DB, ed. Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ: John Wiley & Sons Inc; 1987.
dc.identifier.citedreferenceHelwick C. Dr. Susan Love: time to address “collateral damage” of breast cancer treatment. http://www.ascopost.com/issues/may‐25‐2016/dr‐susan‐love‐time‐to‐address‐collateral‐damage‐of‐breast‐cancer‐treatment/. Accessed December 28, 2016.
dc.identifier.citedreferenceRunowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016; 66: 43 – 73.
dc.identifier.citedreferenceMontemurro F, Mittica G, Cagnazzo C, et al. Self‐evaluation of adjuvant chemotherapy‐related adverse effects by patients with breast cancer. JAMA Oncol. 2016; 2: 445 – 452.
dc.identifier.citedreferenceByar KL, Berger AM, Bakken SL, Cetak MA. Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. Oncol Nurs Forum. 2006; 33: E18 – E26.
dc.identifier.citedreferenceHarrison JM, Stella PJ, LaVasseur B, et al. Toxicity‐related factors associated with use of services among community oncology patients. J Clin Oncol. 2016; 12: e818 – e827.
dc.identifier.citedreferenceJanz NK, Friese CR, Li Y, Graff JJ, Hamilton AS, Hawley ST. Emotional well‐being years post‐treatment for breast cancer: prospective, multi‐ethnic, and population‐based analysis. J Cancer Surviv. 2014; 8: 131 – 142.
dc.identifier.citedreferenceHamelinck VC, Bastiaannet E, Pieterse AH, et al. Patients’ preferences for surgical and adjuvant systemic treatment in early breast cancer: a systematic review. Cancer Treat Rev. 2014; 40: 1005 – 1018.
dc.identifier.citedreferenceBasch E, Deal AM, Kris MG, et al. Symptom monitoring with patient‐reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016; 34: 557 – 565.
dc.identifier.citedreferenceMooney KH, Beck SL, Friedman RH, Farzanfar R, Wong B. Automated monitoring of symptoms during ambulatory chemotherapy and oncology providers’ use of the information: a randomized controlled clinical trial. Support Care Cancer. 2014; 22: 2343 – 2350.
dc.identifier.citedreferenceDi Maio M, Basch E, Bryce J, Perrone F. Patient‐reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol. 2016; 13: 319 – 325.
dc.identifier.citedreferenceLyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose‐intensity in aggressive non‐Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004; 22: 4302 – 4311.
dc.identifier.citedreferenceLyman GH, Dale DC, Crawford J. Incidence and predictors of low dose‐intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003; 21: 4524 – 4531.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr30547_am.pdf
Size:
1.275MB
Format:
PDF
View/Open
Name:
cncr30547.pdf
Size:
506.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.